Elvitegravir
Elvitegravir is an antiviral compound that inhibits integrase activity. This compound is clinically used to treat HIV infection.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1890122
| Cas No. |
697761-98-1 |
|---|---|
| Purity |
≥98% |
| Formula |
C23H23ClFNO5 |
| Formula Wt. |
447.88 |
| IUPAC Name |
6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid |
| Appearance |
White to off white powder |
Reviriego C. Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17. PMID: 24696866.
Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008 Jan;82(2):764-74. PMID: 17977962.
